What to know before key FDA meeting on Aimmune peanut allergy therapy

What to know before key FDA meeting on Aimmune peanut allergy therapy

STAT Plus: 7 things to know about Aimmune’s peanut allergy therapy ahead of a pivotal FDA meeting

By ADAM FEUERSTEIN

ADOBE

The convening of the FDA advisory panel, scheduled to meet — and vote — on Sept. 13, will be a pivotal moment for Aimmune Therapeutics.

READ MORE